Antibodies to Amyloid Beta
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2013/071567, filed Oct 15, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,834,598 | Antibodies to Amyloid Beta In force · High confidence | MedImmune Limited | In force | High confidence | ||
| US 10,662,239 | Antibodies to Amyloid Beta In force · Low confidence | MedImmune Limited | In force | Low confidence | ||
| US 11,286,297 | Antibodies to Amyloid Beta In force · Low confidence | MedImmune Limited | In force | Low confidence | ||
| US 12,344,664 | Antibodies to Amyloid Beta In force · Medium confidence | MedImmune Limited | In force | Medium confidence | ||
| US 12,098,191 | Antibodies to Amyloid Beta In force · Low confidence | MedImmune Limited | In force | Low confidence | ||
| Application 19/221,202 | Antibodies to Amyloid Beta Pending Not granted | MedImmune Limited | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by MedImmune, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.